CAR T-cell therapy market poised for $3b growth until 2028

The market is growing at a CAGR of 16.83%.

The global market for CAR T-cell therapy is projected to grow by $3.02b until 2028 at an estimated compound annual growth rate (CAGR) of 16.83%.

A report by Technavio revealed that the market is experiencing notable due to an increasing number of product approvals and clinical trials, driven by a rising prevalence of cancer cases, particularly leukaemia and lymphoma.

“The number of clinical trials for CAR-T cell therapies has surged, with 415 trials registered on Clinicaltrials.gov as of 23 November 2022,” the report said.

In line with this, supportive government policies and rising expenditures on research and development are expected to further drive market growth.

By end-user, the hospital segment is poised to dominate the market due to being primary administrators of CAR T-cell therapy treatments.

“Hospitals closely monitor patients during therapy for adverse reactions and provide post-treatment follow-up care. The growing number of cancer treatments in hospitals is expected to fuel market growth,” the report added.

However, the market is also expected to face challenges associated with high costs influenced by complex manufacturing processes, the treatment’s personalised nature, and specialised healthcare infrastructure requirements.

According to Technavio, CAR T-cell acquisition costs range from $373k to $475k per infusion, excluding additional procedures or facility fees. 

Meanwhile, the inpatient setting for therapy administration contributes to an additional cost that ranges from $79.5k to $85.3k.

Moreover, securing financial backing for clinical trials, and ensuring scalability, cost-effectiveness, and product consistency serve as barriers that may impede the market’s growth within the forecast period.